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ABSTRACT
The protein NOD- like receptor pyrin domain containing 12 (NLRP12) comes from a family of
protein receptors with a wide range of functions including fertility as well as anti-inflammatory
properties. The biological role of NLRP12 is poorly understood: research on the mechanisms
behind its function and/or activation remains contradictory between different cell models.
Current research suggests its involvement in a multi-protein complex named the inflammasome.
The alternative hypothesis that has also been proposed is that NLRP12 is not a part of the
inflammasome, rather it negatively regulates a transcription factor known as NF-𝜅B down stream
of Toll-like receptors. NLRP12 is important because if it is mutated, research has found it can
cause severe inflammation in the colon (colitis) and even lead to certain types of colorectal
cancer. Other experiments have shown that NLRP12 is also responsible for causing a wide range
of autoimmune diseases in humans. Thus, if we can control NLRP12, we might be able to
provide better treatments for these debilitating diseases. I propose that by performing a yeast-2hybrid screen, that I can find new proteins that can unveil NLRP12’s function(s). My research
has identified three ubiquitin associated proteins that interact with NLRP12; including: CUL3,
RNF2, and COPS5 proteins. The functions of all three of these proteins lead me to believe
NLRP12 may participate in a ubiquitin pathway to regulate inflammation. In addition, I found
NLRP12 also interacted with IFIT1, which is known to interfere with virus infection and is also
associated with ubiquitination. This new information could help provide details to unveiling how
NLRP12 functions in relation to different proteins it interacts with in vivo.
KEYWORDS: NOD-like receptors, yeast-2-hybrid, inflammation, colitis, anti-inflammatory,
ubiquitin, NF-𝜅B, autoimmune disease.
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INTRODUCTION

According to a study done by the National Institutes of Health, nearly twenty percent of
the entire U.S. population have some type of inflammatory disease (Pahwa, R. and Jialal, 2018).
Crohn’s disease and inflammatory bowel syndrome (IBS) are included in this list and are
responsible for causing chronic pain and discomfort. Recent research has found that chronic
colon inflammation is now one of the leading causes of colorectal cancer (Wang, ZH. and Fang,
JY. 2014). In other words, inflammatory diseases such as Crohn’s and IBS might be the least of
our worries, as they contribute to the development of life-threatening cancer. Research has tried
to find new ways for the immune system to alleviate chronic inflammation naturally, instead of
the use of steroids or other drugs; giving new hope to patients in its wake.
It is no secret that cancer is on the rise. According to the Center for Disease Control,
cancer is the second leading cause of death behind heart disease in the United States. Advancing
technology and interminable research has helped us to come a long way battling the numerous
types of cancer and its victims in which it ensnares.

The Immune System
Overview. The immune system is comprised of both the innate and adaptive immune
response systems that are independent parts that work together in a synergistic manner for a
common goal: protect the host from succumbing to infection. It does this through recognition via
cellular receptors known as pattern recognition receptors (PRRs). This super-family of receptors
are located both intracellularly and extracellularly, which aids in a wide range of pathogen
recognition. These receptors also help to detect non-self-antigens that can be categorized as
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damage associated molecular patterns (DAMPs), which could include damage signals such as
sudden ion influx that indicate cellular structural damage. Antigens could also register as
pathogen associated molecular patterns (PAMPs), which are pathogen components such as
lipids, proteins, and nucleic acids. Both DAMPs and PAMPs reiterate that detection of non-selfantigens is crucial to stimulate the correct response and prevent unnecessary damage to the host
(Jacobs, SR. and Damania, B. 2012).
Pattern Recognition Receptors. The innate immune system is comprised of several
germline-encoded recognition proteins. These proteins are combined into one super-family
called pattern recognition receptors (PRRs). PRRs are expressed in several cell types and there
are several families encompassed within the super-family. They are expressed in several innate
immune cells including monocytes, macrophages, dendritic cells, endothelial cells, and
neutrophils. Some PRRs have also been found in several adaptive immune cells as well. (Tuncer,
S. et al. 2014). Family members include transmembrane proteins called Toll-like receptors
(TLRs), retinoic acid inducible gene-I (RIG-I)-like receptors (RLRs), and cytoplasmic receptors
known as NOD-like receptors (NLRs) (Jacobs, SR. and Damania, B. 2012). These receptors are
responsible for detecting both PAMPs and DAMPS. Altogether, these proteins are the scaffold to
how the innate immune system functions (Lupfer, CR. and Kanneganti, KD. 2011). If one of
these mechanisms malfunctions (i.e. activated excessively) the whole system breaks down,
potentially leading to inflammatory diseases. For example, dysregulation of nucleotide-binding
oligomerization domain proteins 1 and 2 (NOD1 and NOD2) leads to the development of
Crohn’s disease (CD) (Caruso, R. et al. 2014). It has been studied that Inflammatory Bowel
Syndrome (IBS) and CD have been linked to overzealous innate signaling of the Nuclear Factor
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kappa-light-chain of activated B cells (NF-𝜅B) and Mitogen associated protein
kinase/extracellular signal related kinase (MAPK/ERK) pathways (Caruso, R. et al. 2014).
NOD-like Receptors (NLRs). Mammalian NLRs share structural homology with plant
innate receptors known as R proteins. These proteins help plants detect and respond to infection
(Tuncer, et al. 2014). These R proteins and NLRs have a homologous three leaflet structure that
includes an N-terminal effector domain that mediates protein-protein interactions necessary for
function, a central nucleotide binding domain (NBD) that contains a Walker A and B motif
which are highly conserved regions necessary for ATP hydrolysis, and a C-terminus leucine rich
repeating (LRR) domain that is thought to be necessary for ligand binding and autoregulation
(Ye, Z. et al. 2007). Research has found that there are 22 known NLR proteins and, since their
discovery in 2005, nearly half remain to be characterized. These 22 proteins are further divided
into four subfamilies based on their effector domains: NLRA, NLRB, NLRP which have Pyrin
domains, and NLRC which has a CARD effector domain. NLRP proteins, specifically NLRP12,
is what I am most interested in. The NLR proteins can also be categorized based on their
function including: inflammasome assembly, signal transduction, transcription activation, and
autophagy (Tuncer, S. et al. 2014; Kim, Y.bet al. 2016). Inflammasomes are multi-protein
complexes that form upon stimulation with certain DAMPs. The protein complex consists of the
NLR protein associating with apoptosis associated speck protein (ASC) via either CARD-CARD
or PYRIN-PYRIN domain oligomerization, Caspase-1, which upon association recruits inactive
forms of cytokine proteins including pro-IL-1𝛽 or pro-IL-18 which are activated via
inflammasome formation. The release of these pro-inflammatory cytokines stimulates a robust
immune response based upon the source of the stimuli (Chen, Y. 2014). Some NLRs, NOD1,
NOD2, NLRP6, and NLRP12, have been found to activate or suppress the NF-𝜅B inflammatory
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signaling pathway via signal transduction. Autophagy, which is the recycling of the cellular
components via autodigestion, has not been shown to include very many NLR proteins in its
pathway. However, NOD1 and NOD2 are among the only two NLR proteins to be associated
with the autophagy pathway to date. It has been shown that NOD1 and NOD2 can induce the
autophagy pathway via association with autophagy-related gene (ATG) protein ATG16LI
(Tuncer, S. et al. 2014; Kim et al. 2016). ATG16LI associates with ATG12 and ATG5 to form
the ATG12 conjugation system that is required for autophagosome formation (Naser, SA. et al.
2012). Lastly, a fourth category, not previously mentioned, associates NLR proteins having
inhibitory effects on inflammatory signaling pathways. One specific NLR associated with this
function is NLRP12 (Lupfer, CR. and Kanneganti, KD. 2013). How NLRP12 performs this
function (amongst others) is what I am most interested in.

NLRP12 and Its Many Functions
Overview of Structure and Function(s). NLR Family Pyrin Domain Containing 12
(NLRP12) is a protein that has been studied extensively for nearly two decades. However, the
way that NLRP12 functions is still under scrutiny. It is believed that NLRP12 promotes
inflammatory signaling in neutrophils upon differentiation via the MAPK/ERK signaling
pathway (Wang Q. et al. 2018). On the other hand, it has also been seen that NLRP12 deficient
mice develop large cancerous growths within their colorectal epithelium. It was concluded that
NLRP12 could be responsible for modulating certain cytokines which have been found to
promote cancerous growths; allowing them to spiral out of control (Zaki, MH. et al. 2011).
In addition, recent research depicts that NLRP12 does not suppress inflammation, but it
exacerbates it by forming a common multi-protein complex called an inflammasome (Vladimer,
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GI. et al. 2012). Regardless of the study, it appears that NLRP12 has been found to serve several
different functions throughout different types of immune cells. However, it has not been studied
why these discrepancies in data exist. Therefore, I believe that future research should address the
possibility that NLRP12’s function varies based upon the splice form it has originated from upon
its formation. NLRP12’s full-length cDNA open-reading frame encodes 10 exons that can be
spliced into at least four different variations. The first isoform is NLRP12 with all 10 exons (fulllength), the second isoform lacks exon 9, the third lacks exons 7 and 8, and the last isoform lacks
exons 7 through 9. Interestingly, the only differences between each of the isoforms lies within
differential splicing of the LRR domain (Williams, KL. et al. 2003; Lich, JD. et al. 2007). Thus, I
conclude that each of these isoforms must bind to a different ligand that determines how
NLRP12 will function. I believe more research should compare these isoforms with the same in
vitro and in vivo experiments that have been completed so far. In addition, more research should
look to see if there are more than four isoforms and if these isoforms can be modified
epigenetically based upon which cell NLRP12 is being expressed.
As previously mentioned, NLRP12 has been found to have several different functions.
The question remains if NLRP12 performs all these functions at once, or how it is spliced prior
to translation into a functional protein determines its fate. NLRP12 has three distinct domains it
shares with its family members: Pyrin, NACHT, and Leucine Rich Repeat (LRR). Its NACHT
domain allows the activation of the binding complex through ATP-dependent oligomerization.
The Pyrin domain, which is found at the N-terminus, mediates homotypic protein-protein
interactions for downstream signaling. Lastly, the LRR domain is found on the C-terminus and
functions in ligand sensing and autoregulation (Tuncer, S. et al.2014). These domains work
together to allow NLRP12 to be functional. Although research has identified the different
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domains of NLRP12, not much has been done to determine the mechanisms that allow proteins
to interact with NLRP12 upon its activation. More research still needs to be done to see which
domain(s) may be involved within these different interactions.
Inflammasome Formation or Anti-Inflammatory Regulator. Inflammasome
formation concurs via associations between several NLRs (NLRP1,NLRP3, NLRP6, NLRC4,
and NLRP12) (Zhong, Y. et al. 2013) via their CARD or PYRIN domain via the CARD or
PYRIN domain of apoptosis associated speck protein (ASC) that acts as an adaptor protein to
connect the NLR protein with pro-caspase-1 protein. Upon these associations, the pro form of
IL-1𝛽 is then cleaved into its active form and released into circulation (Chen, GY. 2014). Recent
research has focused around the conundrum of whether NLRP12 takes part in the formation of
an inflammasome complex. NLRP12 was one of the first NLR proteins to be believed to form an
inflammasome (Wang, L. et al. 2002). In 2016, Cai, S. et al conducted similar experiments with
human macrophages, neutrophils, and dendritic cells. They observed a decrease in proinflammatory cytokines (IL-18 and IL-1𝛽). These results suggest NLRP12 inflammasome
activation (Cai, S. et al. 2016). Whether or not NLRP12 was acting alone in the cytokine
production or other inflammasome were contributing to the cytokine storm was not evaluated. In
vivo results have shown NLRP12 deficient mice succumb to Yersinia pestis infection and
exhibited lower amounts of inflammasome associated pro-inflammatory cytokines IL-18 and IL1𝛽. These results indicated that upon infection of Y. pestis NLRP12 serves a pro-inflammatory
role to reduce the bacterial load and provide bacterial resistance (Vladimer, GI. et al. 2012). A
year later another article was published claiming the opposite was true. Allen, I. et al, claimed
that upon stimulation with Klebsiella pneumoniae or Mycobacterium tuberculosis, mice showed
no significant difference in the release of IL-1𝛽 in NLRP12 deficient mice compared to wild
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type mice for both their in vitro and in vivo experiments (Allen, IC. et al. 2013). They claimed
that NLRP12 does not play a role in inflammasome formation in response to K. pneumoniae and
M. tuberculosis. These results are supported by recent findings in NLRP12 deficient mice with
Brucella abortus and Salmonella typhimurium infection which showed NLRP12 deficient mice
were found to have increased bacterial resistance. In this model, it appears NLRP12 served as a
negative regulator of pro-inflammatory signaling via NF-𝜅B/MAPK/ERK signaling pathways
(Silveira, TN et al. 2017; Zaki, MH. et al. 2014). Nevertheless, research is still grasping for
straws trying to pin down the exact mechanism NLRP12 mediates during pathogenic infections.
One problem in comparing these studies is that different background strains of mice and
different bacteria were used, which may play a role in the differences observed. However, it may
take some time to be able to examine all possibilities of functionality in certain infections.
Immune Cell Migration. A newer function of NLRP12 that has been introduced is that
NLRP12 is serving a role in the recruitment of innate cells during the early stages of infection.
Several studies have been conducted and, in response to K. pneumoniae infection, NLRP12
deficient mice showed a decrease in both dendritic and neutrophil recruitment chemokines
(CXCL1, CCR7, and CXCR4 ligands) (Cai, S. et al. 2016). Interestingly, similar findings were
found in NLRP12 deficient mice in response to influenza A virus infection. However, the
outcome was beneficial to the deficient mice. The NLRP12 deficient mice survived lethal flu
infection because of the lack of neutrophil recruitment via CXCL1 secretions (Hornick, E. et al.
2018). I believe the difference in outcomes must stress the importance of NLRP12 as a
modulator (whether it be pro or anti-inflammatory) when it comes to pathogenic infections.
NLRP12 must play a role in controlling how potent or mild an immune response must be based
on the type of infection and location of that infection.
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NLRP12 Diseases and Altered Pathologies
Familial Cold Autoinflammatory Syndrome Type 2 (FCAS2). NLRP12 (PYPAF7/NALP12/Monarch-1) was one of the first NLRs to be discovered. However, currently it is one
of the most dynamic NLRs when it comes to how it functions in vivo. Specifically, it has been
found that certain missense mutations in the NLRP12 gene also causes a disease called Familial
Cold Autoinflammatory Syndrome Type 2 (FCAS2) and certain skin diseases; such as atopic
dermatitis (Zamoshnikova, A.et al. 2016; Jeru et al. 2008; Lukens et al. 2015). The
characteristics of FCAS2 include recurrent fever, rash, and/or joint pain when exposed to cold
temperatures (Xia et al. 2016). The cause of such diseases is a result in a malfunction in
modulation of inflammation, specifically NF-𝜅B signaling pathway within myeloid cells as well
as T cells (Thaiss, CA. and Elinav, E. 2015). The result is an overzealous and recurrent immune
response. Treatment with anti-IL-1, which has shown to work for NLRP3 related diseases, have
had limited success in FCAS2. Inquiry shows that patients treated with IL-1 inhibitor therapies
return within less than 18 months resistant to the drug administered. (Zhong, Y. et al. 2013).
Jeru et al. proposes that NLRP12 inflammatory disease must be caused by overreaction of the
NLRP12 inflammasome (increased CASP-1 production) as well as increased migration of innate
immune cells (Jeru, I et al. 2011). However, atopic dermatitis and FCAS2 are not the only
autoimmune diseases that are found to be associated with dysfunctional NLRP12 protein
expression.
Dysfunctional Regulatory T Cell Diseases. Recent research has veered the focus of
NLRP12 inflammatory disease from experiments in innate immune cells to adaptive immune
cells in vivo. Gurung, P.and Kanneganti, KD. mentioned that the cause of these diseases comes
from dysregulation in T cells, but most research for these diseases have been done in innate
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immune cells. Preliminary data showed an overexpression of NLRP12 in T cells compared to
that of other innate immune cells (ie. DCs and macrophages). In addition, adoptive transfer
experiments showed NLRP12 deficient T cells given to mice resulted in disease pathologies
which resembled that of atopic dermatitis and colitis; never shown in mice experiments to date.
More importantly, Gurung, P. and Kanneganti, KD. believe IL-4 blocking treatments would be
more beneficial to these patients because mice experiments showed increased Th2 cytokine
production which resulted in similar disease pathology as mentioned above. Furthermore,
experiments with NLRP12 deficient mice showed increased EAE and, upon anti- IL-4 treatment,
showed remarkable improvement proving the overproduction of such cytokines can cause other
autoimmune diseases as well (Gurung, P. and Kanneganti, KD. 2015; Lukens, JR. et al. 2016;
Thaiss, CA. and Elinav, E. 2015).
Cancer Tumorigenesis. One of the more commonly known diseases associated with
NLRP12 deficiencies is it has been shown to cause colorectal inflammation. Both Zaki, MH. et
al. and Allen, I. et al. have conducted NLRP12 deficient mice models that display its role in
modulating colon inflammation. However, their mechanisms show that the key factor in
modulation of cancer tumorigenesis lies within NF-𝜅B signaling regulation. First, Zaki, MH. et
al. described NLRP12 deficient mice had increased canonical NF-𝜅B signaling (Figure 1) (IL-6,
IKB𝛼, TNF𝛼, STAT3, and ERK), which they believed to contribute to the progression of colon
tumorigenesis. They believe this mouse model demonstrates a mechanism of irregular response
between the host immune system and microflora in the gut. In other words, the immune system
is initiating a hypersensitive response that is unnecessary and causing hyperinflammation in the
gut. Research has shown that constant inflammation is a major contributor to cancer
tumorigenesis (Zaki, MH. et al. 2011). Similarly, Allen, I. et al showed that NLRP12 deficient
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mice were highly susceptible to colitis and tumor production, but the mechanism was different.
Their data showed an increase in non-canonical NF-𝜅B signaling (Figure 2) via cancer inducing
genes of CXCL12 and CXCL12. In 2014, Allen, I et al. characterized that the non-canonical NF𝜅B pathway is regulated by the degradation of TRAF3 that leads to the activation of NIK and
NLRP12 mediation of this pathway is crucial in prevention of disease progression (Allen, I. et al.
2014).

NLRP12 Known Protein-Protein Interactions
Interleukin-1 Receptor Associated Kinase 1 (IRAK1). IRAK1 is a well-known
serine/threonine kinase protein that initiates downstream NF-𝜅B signaling via TLR and IL-1R
pathways. In preliminary data, Dr. Christopher Lupfer displayed NLRP12 associates with Fasassociated protein 1 (FAF-1) and with IRAK1. Additionally, recent research has shown that
NLRP12 expression is reduced upon both TLR signaling and Tumor-necrosis factor (TNF)
signaling pathways. Interestingly, NLRP12 interferes with both TLR 2 and 4 activation via its
association with IRAK1 (Figure 1). It was found that this association prevented IRAK1 from
hyperphosphorylation that is required for associating with TRAF6 and thereby inhibiting
pathway progression (Williams, KL. et al. 2015) and leading to IRAK1 degradation through the
26S proteasome (Lich, JD. et al. 2007). This mechanism is a great example that displays how
NLRP12 modulates the canonical NF-𝜅B signaling pathway. However, the exact mechanisms
behind how NLRP12 associates with IRAK-1 is still to be determined. Recent research has also
investigated the possibility of NLRP12 inhibiting canonical signaling downstream of IRAK-1
with a similar mechanism. It was found that NLRP12 regulates the non-canonical signaling
pathway through NIK degradation (Lich, JD. et al. 2007).
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NIK and TRAF3 in Non-Canonical NF-𝜿B Signaling. NF-𝜅B inducing kinase (NIK) is
a well-known protein kinase that is unique in its function within the N-F𝜅B pathway. Unlike
canonical signaling, which has many upstream effectors that can stimulate downstream signaling
and activation, non-canonical signaling only has one known regulatory kinase (NIK) (Lich, JD et
al. 2007; Chen, Y. 2014). How NLRP12 mediates non-canonical signaling via NIK is through its
proteasomal degradation (Arthur, JC. et al. 2010) upon interaction with NLRP12’s NOD and
LRR domains (Tuncer, S. et al. 2014). After NIK becomes activated, it recruits IKK𝛼 and p100,
which leads to proteasomal modification of the NF-𝜅B subunit into p52, which translocates to
the nucleus to induce transcription of certain chemokines including CXCL12/13 and CCL5
(Lich, JD. et al. 2007). Importantly, these chemokines are known to be a key factor in
tumorigenesis (Allen, I. et al. 2012). NLRP12 has concurrently been shown to interact with TNF
receptor associated factor 3 (TRAF3), which is also linked with the non-canonical NF-𝜅B
signaling pathway. It has been shown that NLRP12 associates with TRAF3 via the TRAF2TRAF3-CIAP1-CIAP2 complex, which is known to be responsible for constant NIK
ubiquitination and degradation that is required for its modulation to keep its NF-𝜅B processing
of p100 at basal levels and serve as a negative feedback loop of NIK activation levels (Razani, B.
et al. 2011;Sun, SC. 2011).
Other Known Protein Interactions with NLRP12. Since NLRP12’s discovery nearly
twenty years ago, research has implicated numerous proteins that mediate its function. In
addition to the three already discussed, there are several more that are worth mentioning. One of
the first known proteins to associate with NLRP12 was B lymphocyte-induced maturation
protein-1 (Blimp-1). This zinc-finger protein has come to be known as the master regulator of the
regulator via histones 3 acetylation (Lord, C. et al. 2009; Shi, F. et al. 2016). NLRP12 not only
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has its own modulator, it also has its own chaperone complex of Hsp70/90 that prevents its
degradation while it tags other proteins for proteasomal degradation (Arthur, JC et al. 2007). All
of which suggest several different functional applications of NLRP12 and its many isoforms that
could be differentially expressed in several immune cells. One of the most compelling
interactions that could lead to several breakthroughs in NLRP12 activation is its association with
NOD1 and NOD2. These NLR family proteins are mostly known for immunity to different
bacterial antigens. However, it has been seen that this complex formulation can be stimulated via
viral antigens as well. NOD1 and NOD2 can interact with RIPK2 via their CARD domains and
recruit several E3 ubiquitin ligases (TRAFs, CIAP1/2, ITCH, and XIAP) which leads to K63
ubiquitination of RIPK2 which leads to downstream AP-1 and NF-𝜅B transcription factor
activation (Zhong, Y. et al. 2013). However, NLRP12 has been known to associate with NOD 1
and 2 via a linker protein (FAF-1). The function of this relationship remains undetermined
(Wagner, RN. 2009). Lastly, NLRP12 has been known to associate with TRIM25 (another E3
ubiquitin ligase) after viral infection through the RIG-I pathway (Chen, ST. 2019). Other NLRs
are known to associate to NOD1 and 2 via the autophagy protein ATG16L via which has been
shown to be critical in autophagosome formation via the NODosome formation so the question
remains if NLRP12 could as well (Coutermarsh-Ott, S. et al. 2016).

NF-𝜅B Inflammatory Signaling Pathway
The nuclear factor kappa B (NF-𝜅B) was first discovered by Ranjan Sen in 1986. NF-𝜅B
is a family of proteins that include: RelA, RelB, c-Rel, p50/p105, and p52/p100. All of which, in
their inactive form, bind to the protein I𝜅B via their Rel homology domain (RBD) (Ghosh, S.
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and Hayden, M. 2018). The NF-𝜅B signaling pathway can be divided into two categories:
classical (canonical) and alternative (non-canonical) pathways.
Canonical Signaling Pathway. Extensive research has been done on both the classical
and alternative NF-𝜅B signaling pathways. Lich, J. et al. describes that classical pathway
activation occurs very rapidly following ligand binding of several cell membrane receptors,
including TLRs, which subsequently promotes NF-𝜅B activation. Brown, K. et al. stated that
upon the activation of IKKs (𝛼/𝛽/𝜆) the IKKs form a complex with NF-𝜅B essential modulator
(NEMO) and become capable of phosphorylating I𝜅B (Inhibitor of 𝜅B) which induces the
release of several NF-𝜅B subunits to translocate to the nucleus to initiate transcription of
necessary cytokines and other pro-inflammatory genes (Brown, K. et al. 2008). NF𝜅B also
activates gene expression of NF-𝜅B genes such as p100 and IκB𝛼 (Lich, J. 2007). If this were
not complicated enough, there is an entirely different pathway that includes hundreds more
proteins that research still is unveiling (Figure 1).
Non-Canonical Signaling Pathway. More research has focused on the non-canonical
pathway in recent years. However, it is still considered the least understood NF-𝜅B signaling
pathway. Non-canonical signaling has been found to be important for B and T cell survival,
development, and lymphoid organogenesis (Brown, K. et al. 2008). The non-canonical pathway
focuses mainly on the further processing of p100 instead of IκB𝛼 degradation (Figure 2). In
addition, the NF-𝜅B-inducing kinase (NIK), with the help of IκB𝛼, work to induce proteolytic
processing of p100 into p52. It has been shown that NIK is under constitutive degradation itself
under normal conditions by TNF receptor associated factor-3 (TRAF3) (Sun, SC. 2013). Once
NIK becomes stabilized, the non-canonical NF-𝜅B pathway can continue.
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Modulating the Pathway.
As complicated as the NF-𝜅B pathways are, it is critical that they are kept in check. There
are several post-translational methods that have been found to modulate these signaling
pathways. In layman terms: these modulators act as sequenced traffic lights to regulate signals
and prevent excessive inflammation. Post-translational modifications involved in the NF-𝜅B
signaling pathway include ubiquitination, de-ubiquitination, SUMOylation and many more. I
will only discuss ubiquitination because it is directly relevant to my research.
Ubiquitination. Briefly, ubiquitination is the covalent attachment of a protein (ubiquitin)
to a substrate protein. Upon attachment of this small protein (8.5 kDA), several outcomes may
occur. These may include control of cell cycle division, differentiation, DNA repair or its most
pivotal role: protein stability. Ubiquitination is ubiquitous throughout the cell and evolutionary
history. Ubiquitin is attached to a protein of interest via a series of activation (E1 enzyme),
conjugation (E2 enzyme), and ligation (E3 enzyme) proteins. It acts as a cell’s bucket brigade as
the small ubiquitin protein is passed along the three enzymes ending with ubiquitin being
attached to the protein of interest (Swatek, K. and Komander, D. 2016). One common purpose
for ubiquitination/poly-ubiquitination of a protein is because the protein may become destined
for degradation via the proteasome (ie. The woodchipper of the cell). This process is called the
Ubiquitin-proteasome system (UPS) and its main function is to regulate protein abundance and
turnover. The mechanism behind such a task lies within ubiquitin’s seven lysine residues (Lys6,
11,27, 29, 48, and 63). For the sake of simplicity I will only be discussing Lys48 (K48) and
Lys63 (K63) ubiquitination mechanisms and their downstream relevance (Collins, P. et al.
2016). Upon poly-ubiquitination, the ubiquitin tags are stacked one on top of the other in a
sequential fashion. The purpose for this mechanism is modulation of how active a protein will
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become which is beneficial in signaling pathways that may contribute to forceful immune
responses (ie. NF-𝜅B/MAPK/ERK). Interestingly, K48 poly-ubiquitination serves as a
degradation signal in the canonical NF-𝜅B pathway to the 26S proteasome. One example in this
pathway (Figure 1) is upon recognition of the pro-inflammatory cytokine IL-1, via the IL-1
receptor (IL-1R), the protein MyD88 associates with IL-1R and IRAK1/4 which allows TRAF6
(E3 Ligase) to associate and through K48 ubiquitination, TRAF6 tags IRAK1/4 for degradation
via the 26S proteasome in order for the NEMO complex to be recruited for the pathway to
continue (Courtois. G. and Fauvarque, MO. 2018). K63-poly-ubiquitination was the first lysine
residue to be discovered and is known to be associated with modulating protein activity as well
as many other functions that range from protein-protein interactions to endocytosis. In other
words, K63 acts as a flag or signal to other proteins downstream that give them a “go” signal to
either associate or mediate other cellular functions. K63 ubiquitin chains are also said to be
favored with de-ubiquitin proteins such as USP48. Ubiquitin-Specific Proteins (USP) are
especially important in the NF-𝜅B signaling pathway. USP48 is known to bind with COP9
signalosome to stabilize NF-𝜅B subunit p65 by removing K48 ubiquitin chains within the
nucleus. Actions such as this help to enhance or dampen pro-inflammatory genes during an
infection (Collins, P. et al. 2016).
NLRP12 Involvement. Recent research has shown that NLRP12 is able to alter the
signaling within both the canonical and non-canonical NF-𝜅B signaling pathways (Ting, JP et al.
2010). Lich, J. et al. also reported that there is a possibility that NLRP12 modulates both the
classical and alternative pathways. Research has found that NLRP12 induces the degradation of
NIK by binding to it, which in turn modulates any further downstream NF-𝜅B signaling.
Additionally, NLRP12’s NACHT domain directly destabilizes NIK, but more research needs to
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be done to deliberate what affects it has on downstream signaling (Lich, J. et al. 2007). Finally,
NLRP12 can affect the ubiquitination and degradation of proteins in the NF-𝜅B pathway. Chen,
SG. et al. believe that NLRP12 regulates RIG-I activation via the interaction with TRIM25 to
disrupt K63 ubiquitination and activation of RIG-I (Chen, SG. et al. 2019). However, these
findings may be only one of many protein interactions involved to modulate different types of
ubiquitination within this pathway.

Type 1 Interferon Signaling
One of the major anti-viral signaling pathways is the Type I IFN signaling pathway (IFNI). This pathway depends on several transcription factors, mainly NF-𝜅B and IRF3/7. Signaling
of this pathway begins with PRR signaling cascades like TLR7, which is induced by ssRNA or
RIG-I that is activated via dsRNA/5’tripohsophate RNA. These stimulate TRAF3 activation and
thus formation of the IKKε and TBK1 complex which stimulates transcription for type 1
interferons (IFN-α/β) that are highly potent signaling proteins that propel the immune system
into high throttle. Upon viral infection, other stress pathways are also induced (JNK and p38)
which promotes IFN-𝛽 production. IFN-α/β then bind to their receptor in an autocrine and
paracrine manner that results in STAT1/2 pathway activation. Interferon stimulated genes
(ISGs), which are important for creating an unfavorable environment for any viral invader, are
then produced. (Seth, RB. et al. 2006; Li, K. and Zhong, B. 2018).
One ISG, known as interferon-induced proteins with tetratricopeptide repeats 1 (IFIT1),
has been found to be responsible for directly binding to and regulating RNA viral proteins and
functional RNAs, preventing viral replication from occurring. IFIT1 is strongly induced by type
1 interferons and type 3 interferons, which activate the transcription factor STAT1/2 whose job
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is inducing transcription of IFIT genes (Fensterl, V. and Sen, GC. 2015). Recent research has
shown that NLRP12 can directly interact with TRIM25, which in turn disrupts RIG-I activation
(Chen, SG. et al. 2019). I believe there is a possibility NLRP12 could also interact with other
proteins downstream of RIG-I and other PRRs such as IFIT1 to cease anti-viral signaling when it
is no longer necessary.

Scientific Question
Based on previous research, NLRP12 has been known to associate with IRAK1 and other
proteins. My questions include: Does NLRP12 associate with other proteins upstream of IRAK1
upon its activation? What proteins associate with NLRP12 to induce its activation? Do a wide
variety of proteins associate with NLRP12 or is it just ubiquitin or ubiquitin-like proteins? If
NLRP12 is known to destabilize IRAK1, causing it to be degraded by proteasome degradation to
prevent further downstream signaling, what is stabilizing NLRP12 to prevent it from being
degraded? Under what conditions does NLRP12 need to be downregulated or destabilized? How
does NLRP12 control both TCR and TLR signaling pathways of NF𝜅B? All these questions
point to our lack of knowledge regarding the protein-protein interactions of NLRP12.

Scientific Hypothesis
NLRP12 is not a ubiquitin ligase or protease itself, or a kinase or phosphatase. Thus, there
must be additional proteins that interact with NLRP12 to induce its activation. Furthermore,
there are 4 known isoforms of NLRP12, and I hypothesize that these isoforms are activated by
different stimuli and may interact with different proteins following activation. Such differences
could account for the different, and sometime contradictory, functions proposed for NLRP12.
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MATERIALS AND METHODS

Cloning of NLRP12
Using the cDNA template purchased from Addgene, I conducted a polymerase chain
reaction to isolate the NLRP12 gene using gene specific NLRP12 primers (Table 1) and a highfidelity fusion polymerase (Phusion High-Fidelity, ThermoScientific). I was able to isolate the
NLRP12 insert necessary to clone into the pGBKT7 vector (Figure 3 and 4). The PCR conditions
are shown in Table 2. The pGBKT7 vector must be prepped for cloning of NLRP12 using
specific restriction enzymes that must match both the insert and the plasmid vector (Figure 3 and
4). I used FastDigest enymes (ThermoScientific) for NdeI and EcoRI according to the
manufactures protocol. After gel purification of the digested PCR product and plasmid (Figure
5), the pieces were ligated via T4 ligase (Promega) according to the manufactures protocol.
Then, the ligated product was transformed into the 𝛽10 E. coli strain. Transformed E. coli was
plated on LB plates containing 50µg/ml Kanamycin.

Screening E. coli for Positive Clones
After the vector was introduced into bacteria, I picked as many colonies as I could to test
to see if NLRP12 had been successfully cloned into the vector. I did this by diluting the bacteria
into RNAase free water (1:10) and conducting a PCR with primers for the T7 and M13
sequences in the vector plasmid (Table 1). Dream Taq was used as the polymerase
(ThermoScientific) according to the manufacture’s recommendations. The PCR settings are
shown in Table 2. Plasmid from colonies that were positive by PCR (Figure 6) for successful
NLRP12 cloning were then purified and a restriction digest was conducted using NdeI and EcoRI
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to confirm the NLRP12 insert was cloned successfully by examining digested plasmids on a 1%
agarose gel and looking for the correct ~3200bp size bands (Figure 7). Finally, vectors purified
from E. coli that showed the correct band visualized by agarose gel were sequenced via Sanger
sequencing using T7 and M13 primers for sequencing.

Western Blot
Western blot was used to detect protein expression in yeast cells prior to conducting the
2-hybrid screen. Y2H Gold yeast transformed with the pGBKT7-NLRP12 vector were grown
over night in SD-Trp medium and the cells then isolated by centrifugation at 2000 x g for 10
minutes. Yeast cells were combined with a 1:1 ratio of NaOH to sample which mediated lysis of
the yeast cells. These samples were then boiled in SDS loading buffer. A standard western blot
was conducted using an anti-myc epitope antibody that detected the myc tag in frame with the Nterminal region of NLRP12. Blots were imaged using Clarity Western ECL Substrate (Bio-Rad,
A170-5060) and an Azure c300 digital gel imager. All antibodies that were used can be found in
Table 3.

Yeast-2-Hybrid Screen
A yeast-2-hybrid screen was performed using the NLRP12-pGBKT7 plasmid introduced
into Y2H Gold yeast (Frozen-EZ Yeast Transformation II Kit, Zymogen) and mating these yeast
with a human cDNA library in Y187 yeast (Clontech, Normalized HeLa cDNA library)
according to the Matchmaker Gold Yeast-2-Hybrid protocol. Positive yeast colonies were grown
in SD-Leu-Trp broth and plasmids purified via the EZ yeast plasmid kit (Zymogen). Purified
plasmids contained the cDNA of the potential interacting proteins for NLRP12, and the cDNA
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was amplified using the insert screening amplimer primers (Table 1) via PCR using DreamTaq
polymerase and the PCR conditions in Table 2. The results of the PCR are shown in Figure 8.
Amplified PCR products were sequenced by Sanger sequencing and BLASTN used to determine
the gene for each positive cDNA clone.

IFIT1 and Cloning of NLRP12 into a Mammalian Expression Vector
The pCDNA3.1 3xFlag IFIT1 plasmid was purchased from Addgene as a bacterial stab.
The bacteria were grown overnight in LB broth containing 100µg/ml Ampicillin, and the
plasmid was purified. NLRP12 was cloned into the pCDNA3.1 3xMyc plasmid using Gibson
cloning (NEB Gibson cloning kit) according to the manufacturer’s instructions. Primers used for
the PCR amplification of the plasmid and NLRP12 insert are shown in Table 1. The PCR
conditions are shown in table 2. After the Gibson cloning reaction, the plasmid was transformed
into β10 E. coli and plated on LB plates with 100µg/ml ampicillin. Several colonies were
screened by PCR by diluting the bacteria into RNAase free water (1:10) and conducting a PCR
with primers for the T7 and BGH reverse sequences in the vector plasmid (Table 1). Dream Taq
was used as the polymerase (ThermoScientific) according to the manufacture’s
recommendations. The PCR settings are shown in Table 2. Finally, vectors purified from E. coli
that showed the correct band visualized by agarose gel electrophoresis were sent off to be
sequenced via Sanger sequencing.

Transfection of Plasmid into HEK 293 T Cells
Human embryonic kidney (HEK) 293 T cells were plated in 12-well tissue culture plates
at 300,000 cells per well in 1mL DMEM plus 10% fetal bovine serum (FBS), 100U penicillin,
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and 100U streptomycin. The next day, 100 𝜇L of transfection buffer was added to a 1.5 mL tube
for each sample. Next, 2 𝜇g of plasmid was added to the same 1.5 mL tube for each sample.
Lastly, 0.6 μL of the XFECT polymer (Takara/Clonetech) was added to each 1.5 mL tube for
each sample and mixed softly by flicking the tubes. The tubes were then left at room temperature
to incubate for 10 minutes. 100 𝜇L of each DNA/XFECT sample was added to the matching
culture well dropwise. The plates were then left in a 37℃ 5% CO2 incubator for 24 hours.

Western Blot Verification of Protein Expression in HEK 293 T Cells
Twenty-four hours after transfection, I examined protein expression of NLRP12 and
IFIT1 in HEK 293 T cells. The IFIT1 protein has a 3xFlag epitope and NLRP12 protein has a
3xMyc epitope within mammalian expression vectors that were transfected into HEK 293 T
cells. All samples were collected by adding RIPA lysis buffer to plated cells in order to lyse
them. Next, 4x SDS loading dye was added to the cells. Samples were boiled using a heat block
at 95℃. After about 30 minutes, the samples were removed from the heat and electrophoresed on
an 8% polyacrylamide gel. The gel was then transferred onto a PVDF (Polyvinylidene
difluoride). After the transfer was complete, the membranes were blocked in 5% powdered milk
in TBS+0.5% Tween 20 (wash buffer) for approximately 60 minutes. The blocking milk was
then removed, and the primary antibody diluted in fresh blocking buffer (1:2000) was added and
allowed to incubate while slowly rocked at 4℃ overnight. The next day, the primary antibody
was removed, and the membranes were washed with 1x TBST (Wash Buffer) three times before
the secondary antibody was added (1:5000 dilution in blocking buffer) and incubated for at least
2 hours at room temperature. The membranes were then washed six more times with wash
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buffer. Blots were imaged using Clarity Western ECL Substrate (Bio-Rad, A170-5060) and an
Azure c300 digital gel imager. All antibodies that were used can be found in Table 3.

Co-Immunoprecipitation after Transfection into HEK 293 T Cells
The purpose of a co-immunoprecipitation (CO-IP) experiment is to observe or capture
and purify the protein of interest interacting with other proteins or complexes. One can do this by
using target-specific antibodies to detect each protein or complex of interest and observing the
interactions via SDS-Page gel electrophoresis and Western Blotting. In my case I first
overexpressed NLRP12 (pcDNA3-myc-CUL3 mammalian expression vector with c-Myc epitope
tag Addgene plasmid #:19893 was a gift from Yue Xiong)) and IFIT1 (pCDNA3.1-3xFlag-IFIT1
mammalian expression, Addgene plasmid #: 53554) within HEK 293 T Cells. I seeded the cells
in in 60x15 mm tissue culture dishes in DMEM plus 10% fetal bovine serum (FBS), 100U
penicillin, and 100U streptomycin. After 24 hours, I transfected the cells and let them incubate
for 24 hours (See Transfection of Plasmid into HEK 293 T cells). I then removed the media form
the dishes and added 0.5 mL of cold 1% NP40 in PBS with phosphatase and protease inhibitors
(Pierce, ThermoScientific). From this point on I kept the samples on ice. I shook the plates for 30
minutes at 4℃. I then removed the lysate from the plates and put them in 1.5 mL centrifuge
tubes. I spun the cells at 5,000 x g for 10 minutes at 4℃. Next, I put the supernatant into new 1.5
mL centrifuge tubes and added 40 𝜇L of protein A/G beads and shook the cells again at 4℃ for 1
hour. Following the 1-hour incubation period I spun the samples at 2,000 x g for 1 minute at 4℃
and put the supernatant into a third 1.5 mL centrifuge tube and added 2𝜇g of antibody (See Table
3). I then incubated the samples at 4℃ while shaking for 1 more hour. Afterwards, I added 40µL
of A/G beads and put the samples back on the shaker at 4℃ and let them shake overnight. The
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next day, I proceeded to wash the samples 5 times by spinning them at 2,000 x g at 4℃ and
remove the supernatant and adding 1mL of ice cold DPBS. I repeated the wash steps as
necessary and after the last wash was removed, I added 40 𝜇L of 4x SDS loading dye and
proceeded with a Western Blot as above.
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RESULTS

Yeast-2-Hybrid Screen Reveals PPI’s for NLRP12
Based on the plethora of functions ascribed to NLRP12, I hypothesized that there must be
novel proteins that interact with NLRP12 to facilitate these functions. To examine proteinprotein interactions, I used a yeast-2-hybrid screening system. In the yeast-2-hybrid, the GAL4
transcription factor is split it into its activation (AD) and binding domains (BD). The BD is
cloned in frame with the bait protein (NLRP12) and the AD is cloned in frame to the potential
interacting proteins or prey proteins (Human cDNA library) (Figure 9). In this instance we did
not know which proteins interacted with NLRP12, so we screened through the cDNA library. If
the two proteins interact (NLRP12 and a prey protein), the BD and AD of GAL4 are indirectly
brought together to activate transcription of reporter genes (AUR1-C, α-galactosidase, HIS3, and
ADE2 genes) which change the phenotype of the yeast cell. The goal is to grow yeast on media
lacking amino acids, nucleotides, or containing Aureobasidin A or x-α-gal and colonies that
grow and turn blue should indicate positive interactions. Yeast that grows on medial lacking
histidine and adenine indicates a very strong interaction between the bait and prey proteins. In
order to begin this quest, I first needed to clone the full NLRP12 sequence into a cloning vector
(pGBKT7). Unfortunately, I ran into problems doing so and had to resort to separating the full
NLRP12 insert into two halves. (Figure 3). I successfully cloned the first 1570 bp of NLRP12
(which contained the protein interaction domains) (Figures 4-7) and a Y2H screen was
performed. The screen originally revealed eleven proteins, but only six were confirmed (Figure 8
and Table 4). Three of the confirmed proteins: Ring-Finger Protein 2 (RFN2), Cullin 3 (Cul3),
and COP9 signalosome subunit 5 (COPS5) all have ubiquitin-related functions and became main
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proteins of interest. All these interactions have been confirmed in yeast though an individualized
yeast-two-hybrid screen. (Figure 10). Furthermore, the screen revealed a strong interaction with
Interferon Induced Protein with Tetratricopeptide Repeats 1 (IFIT1). IFIT1 (ISG56) functions as
an inhibitor of viral replication downstream of the RIG-I signaling pathway. IFIT1 has a helixturn-helix domain that is known to allow a wide variety of protein-protein interactions (Liu, XY.
et al. 2011). Importantly, its overexpression has been shown to inhibit expression of IRF3,
NF𝜅B, and IFN-𝛽 promoters via disruption of the MITA/TBK1 complex (Li, Y. et al. 2009).
Thus, I believe that NLRP12 interacts with IFIT1 and proteins of the ubiquitin conjugations
system to enhance IFIT1 activity, which in turn enhance the interference with the inflammatory
signaling pathway, preventing transcription of interferon-stimulating genes (ISGs).

Co-Immunoprecipitation Confirm Protein Interaction
In order to confirm the interaction between NLRP12 and IFIT1 that was determined via
previous Yeast-2-Hybrid results (Table 4). I conducted a co-immunoprecipitation experiment
using human HEK 293 T cells transfected with both IFIT1 and NLRP12 (full-length)
mammalian expression vectors (Figure 11 and 12). Preliminary data showed successful
overexpression of both mammalian expression vectors (Figure 13) via western blot. In addition,
co-immunoprecipitation experiments were performed twice to ensure the results were consistent.
These experiments revealed via western blot that IFIT1 and NLRP12 (full-length) do not interact
via overexpression in HEK 293 T cells (Figure 14). However, further experiments could be
conducted to ensure this is the case.
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DISSCUSSION

NLRP12 is a protein that is still misunderstood. After nearly 20 years of research, several
studies have been done to try and identify which proteins interact with NLRP12 upon its
activation. There have been a lot of speculations amongst scientists that NLRP12 is responsible
for modulating intestinal homeostasis. It has been found that NLRP12 is highly expressed in the
gut and acts as a modulator of intestinal inflammation and/or tumorigenesis (Chen, G. 2019).
Allen, I. et al. took it a step farther to say that NLRP12 modulates intestinal inflammation via
regulation of the non-canonical NF-𝜅B and MAPK signaling pathways through the degradation
of NIK via the proteasome-dependent pathway. He went on to show that NLRP12 deficient mice
were found to have increased activity of NIK-regulated genes such as CxcII2 and CxcII3. He
believed that dysregulation of this signaling pathway was causing the NLRP12 deficient mice to
develop cancer within their colonic mucosal tissues. (Allen, I et al. 2013). In summation, he
believes NLRP12 is responsible for modulating a critical checkpoint for inflammation and
tumorigenesis via the modulation of NIK in the non-canonical signaling pathway of NF-𝜅B.
Furthermore, recent research from Chen, L. et al. conducted cohort studies with
monozygotic twins to find that any deficiency in NLRP12 can lead to a change in (or loss of) the
commensal growth in the gut that leads to basal inflammation. Their studies showed that these
symptoms could be reversed with antibody treatment for pro-inflammatory cytokines or with
treatment of Lachnospiraceae commensals (Chen, L. et al. 2017). Findings such as this may be
the key to helping those that suffer from different inflammatory bowel diseases. However, the
mechanism behind which pro-inflammatory cytokines and other signaling pathways that may be
exasperating the problem were not mentioned and more research must be done to determine if it
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is NLRP12 alone causing the basal inflammation, or if it may be other proteins that work with
NLRP12 that may be contributing to the problem. Zaki, MH. et al. believe NLRP12’s main job
in the gut is to maintain homeostasis that may get out of hand if NF-𝜅B/ERK/STAT3 signaling is
not modulated correctly (Zaki, MH. et al. 2011). All in all is seems that when it comes to colonic
inflammation in the gut, NLRP12 plays a key role in its prevention. However, most research in
NLRP12 has focused on the gut, it would be interesting to see a shift to other types of
inflammatory diseases outside of the gut that may lead to similar inflammatory pathologies.
Likewise, other research has suggested that NLRP12 has a pro-inflammatory role as an
inflammasome, which is responsible for the secretion of pro-inflammatory cytokines upon
stimulation of several viral DAMPs and PAMPs (Vladimer, GI et al. 2012). Research has
connected NLRP12 to modulating anti-viral signaling pathways before, but specific proteinprotein interactions with NLRP12 remains unidentified. In addition, research seems to be lacking
in understanding of the functionality NLRP12 may serve amongst different types of infections. I
believe that research should first compare intracellular pathogens with extracellular pathogen
infections and observe whether NLRP12 exhibits a consistent function in either infection. For
example, Allen, IC et al. and Vladimer, GI et al. saw different results because the types of cells
and mice used were not consistent. I am not sure of their reasoning behind this, but maybe
someone can redo these same experiments and compare both extracellular pathogens to each
other and see if their results are consistent with one another.
I have conducted a yeast-two-hybrid screen in hopes of identifying any proteins that
interact with NLRP12 and may be responsible for its functions. I identified several potential
interactions with NLRP12 (SNAPIN, CUL3, RNF2, COPS5, and IFIT1). However, only IFIT1
among them has been examined in human cells. Normally, IFIT1 proteins are known for binding
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to viral RNA and another IFIT protein: IFIT3. These interactions have been found to be critical
for inhibition of viral replication of viruses that lack a 2’-O methylation cap on their RNA
(Johnson, B. et al. 2018). It has also been shown that IFIT1 interacts with both IFIT2 and IFIT3
to enhance its own reactivity to prevent viral translation initiation factors from binding to the
methylated RNA, preventing replication (Habjan, M. et al. 2013). I hypothesized that once the
body senses a virus is no longer a threat, NLRP12 becomes activated and associates with IFIT1
directly and with E3 ubiquitin ligases; then through K48 ubiquitination, IFIT1 is tagged for
destruction. Once IFIT1 is degraded, the antiviral (IFN) signaling pathway is inhibited. However,
coimmunoprecipitation in human cells did not demonstrate an interaction between NLRP12 and
IFIT1. To make a final determination on this interaction, additional research is needed. I believe
these results occurred because the full-length NLRP12 insert was cloned into the mammalian
expression vector. However, only the front portion of NLRP12 (effector domain) revealed the
novel interaction between NLRP12 and IFIT1 in yeast. Therefore, I believe if the effector
domain truncated version of NLRP12 were cloned into the mammalian expression vector and the
co-immunoprecipitation experiment was done again that the results might turn out differently. In
addition, recent research has indicated that NLRP12 activation can be induced via LPS or Nitric
oxide (NO) (Lich, JD. et al. 2007). I think other experiments should be conducted in which 293
T cells are first stimulated with LPS or NO to induce NLRP12 activation first and then coimmunoprecipitation experiments could be conducted to see if the same results could be obtained
in human cells and yeast cells.
I identified three other proteins. It has also been suggested that TRIM25 directly interacts
with NLRP12 during viral infection and K63 ubiquitination of RIG-I was disrupted which
prevented further pro-inflammatory signaling from commencing (Chen, ST. et al. 2019). I
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believe the interaction between NLRP12 and IFIT occurs downstream of RIG-I and TRIM25.
Maybe NLRP12 and other proteins (E3 ligases) interact to disrupt the interaction of IFIT1 with
IFIT3 or other IFIT proteins to terminate the anti-viral signaling pathway. In addition, it may
also signal to other adaptive immunity cells to discontinue pro-inflammatory signaling once the
virus is cleared and promote cell repair from any damage that took place.
For the other interacting proteins, CUL3, RNF2, and COPS5 have the potential to explain
how NLRP12 works with ubiquitin ligases to disrupt the continuation of NF-𝜅B signaling after
an infection is cleared. First, Cullin 3 (CUL3) is a specific E3 ubiquitin ligase that is a part of the
Cullin Ring ubiquitin E3 ligase family (CRL). CRL is a multi-protein complex that consists of
the entire E1, E2, E3 bucket brigade that is required for the addition of ubiquitin onto a target
protein in a process known as ubiquitination (Wang-Shick, R. 2017). Regulation and the
magnitude of proteins involved in this pathway is vastly complex and is beyond the scope of this
thesis. The goal of an E3 ubiquitin ligase is to associate with E1 and E2 proteins in combination
with the target protein complex. Upon association, ubiquitination occurs. Interestingly, the
process of ubiquitination is not a simple process. Ubiquitin can be added one time (monoubiquitination) or up to several times (poly-ubiquitination) (Collins, P. et al. 2016). Regulation of
this system is also complex and will not be discussed in detail here. Yet, CUL3 has been found to
associate with a protein called Cullin Associated and Neddylation Dissociated 1
(CAND1)/(TRIP120A) that is responsible for inhibiting the neddylation (a process analogous to
ubiquitination) of CUL3 by the Skp1, Cullin 1, F box protein complex (SCF). Effectively, this
prevents the ubiquitination of phosphorylated IκB𝛼 by SCF (beta-TrCP) and leads to inhibition
of the NF-𝜅B signaling pathway (Min, KW. et al. 2003). In my opinion, it is not surprising that
NLRP12 was found to associate with CUL3 in this way because NF-𝜅B is sequestered by IκB𝛼
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in its inactive state. Nonetheless, once IKK phosphorylates IκB𝛼 at serine residues 32 and 36, a
destruction motif is then recognized by SCF (beta-TrCP); targeting IκB for degradation which
then frees NF-𝜅B and the signaling pathway continues (Figure1) (Collins, P. et al. 2016). I
believe NLRP12 associates with CUL3 and other E3 ligases to target NF-𝜅B subunits within this
pathway for degradation which would inhibit the pathway from continuing.
On the other hand, Ring finger protein 2 (RNF2) has an entirely different role than
CUL3. Although it is still an E3 ligase, RNF2’s main function is modulating the K-119 residue
ubiquitination on histone H2A. Not much is known specifically about RNF2’s function, but it
has been found to form many complexes with BMI1 and UB2D3 when modulating histone H2A
(Bentley, ML. et al. 2011). In other words, recent research has found RNF2’s main responsibility
is in chromatin modification or gene expression. RNF2 has also been found to work with MDM2
(E3 ligase) in tumor suppression at the DNA level via stabilization of replication fork
progression. Klusmann, I. et al. noted that if either ubiquitin ligase (RFN2 or MDM2) was
suppressed, the other could pick up the slack forreplication fork progression (Klusmann, I. et al.
2018)
Third, COP9 Signalosome Subunit 5 (COPS5) protein is only one of eight E3 ligases to
form the COP9 signalosome which is like the 19S subunit of the 26S proteasome.
Fundamentally, the COP9 signalosome is found to positively regulate E3 ubiquitin ligases;
specifically, those within the CRL family (CUL3) (Wei, N. et al. 2008). It has recently been
discussed that the COP9 signalosome may be a future target for cancer drug research. Schlierf,
A. et al. believe the key is that most cancers associated with malfunctions within the COP9
signalosome are due to a disruption in the management of the several E3 ligases involved. A
disruption in these proteins leads to improper management of several oncogenes and tumor
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suppressors that require close modulation (Schlierf, A. et al. 2016). Their goal is to control the
CRL proteins involved, then the signalosome may be more likely to be controlled which would
lead to better modulation of the oncogenes and tumor suppressors. I believe in order to
understand the mechanism behind how NLRP12 and COPS5 interact a few more missing
proteins need to be identified before it can be fully elucidated. I believe the key to understanding
the mechanism behind how NLRP12 interacts and facilitates modulation of either the canonical
or non-canonical signaling pathway lies within the realm of ubiquitination and other forms of
post-translational modifications via several E3 ligases and other associated proteins.
In summation, I believe my hypothesis regarding NLRP12 interacting with certain
proteins to inhibit pro-inflammatory signaling was preliminarily confirmed for RNF2, CUL3 and
COPS5. Although IFIT1 interacted with NLRP12 in yeast, this interaction was not confirmed in
human cells and additional research is needed to verify or refute these interactions in human cells
to elucidate their functions.
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Table 1. The following primer sequences were used for all cloning experiments.
Primers

Sequences

NLRP12 Ndel
for

GAA TGA CAT ATG ATG CTA CGA ACC GCA GGC AG

NLRP12 Sall
rev

GAT CTT GTC GAC TCA GCA GCC AAT GTC CAA ATA AG

T7 for

TAA TAC GAC TCA CTA TAG GG

M13 rev

CAG GAA ACA GCT ATG ACC

Yeast
Amplimer for

CTA TTC GAT GAT GAA GAT ACC CCA CCA AAC C

Yeast
Amplimer rev

GTG AAC TTG CGG GGT TTT TCA GTA TCT ACG AT

NLRP12
(Gibson) for

TCC TGA TAT CCG CGG TAC CGA TGC TAC GAA CCC CAG

NLRP12
(Gibson) rev

CCT CTA GAT GCA TGC TCG AGT CAG CAG CCA ATG TCC AAA T

3x Myc
(Gibson) for

CTC GAG CAT GCA TCT AGA G

3x Myc
(Gibson) rev

CGG TAC CGC GGA TAT CAG
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Table 2. The following information is the protocols used for all PCR, Colony PCR, and Yeast
Colony PCR experiments.
Protocol

Denaturation

Annealing

Extension
72℃ for 2 min

Number
of Cycles
34

Final
Extension
72℃ for
10 min

PCR
(Cloning)

98℃ for 10 sec

67℃ for 20 sec

Colony
PCR
(Cloning)
Yeast
Colony
PCR

95℃ for 3.5 min

55℃ for 30 sec

72℃ for 2 min

34

72℃ for
10 min

95℃ for 3.5 min

55℃ for 30 sec

72℃ for 2 min

34

72℃ for
10 min

Table 3. The following antibodies were used for all western blot and CO-IP experiments.
Name of Antibody

Detects

Catalog #

Company

Myc-Tag Polyclonal
Antibody

Myc-Tag
EQKLISEEDL
(Mouse)

16286-1-AP

Proteintech

Flag DYKDDDDK
Tag

DYKDDDDK Flag
Epitope (Mouse)

MA1-91878

Invitrogen
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Table 4. The following proteins were shown to interact with NLRP12 via the Y2H screen.
Protein
Protein Name
Abbreviation
SNAPIN
SNAP associated
protein
SPATA22
IFIT1

RNF2
CUL3
COPS5

Spermatogenesis
associates 22
Interferon-induced
Proteins with
Tetratricopeptide
Repeats
Ring Finger Protein-2
Cullin 3
COP9 signalosome
subunit 5

Brief Description
SNARE protein responsible for
vesicle docking and fusion and
regulates neurotransmitter release
Protein required for homologous
recombination in meiosis I
Inhibition of Viral Replication

E-3 ubiquitin-protein ligase
Ubiquitin -protein ligase
Ubiquitin regulator
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Figure 1. A diagram of the classical NF-𝜅B signaling pathway that depicts IRAK1 and TRAF3’s
roles within this pathway. Which also shows where NLRP12 could intervene within this
pathway.

Figure 2. A diagram of the alternative NF-𝜅B signaling pathway that depicts TRAF3’s and
NIK’s roles within the pathway. Which in turn shows where NLRP12 could intervene within the
pathway.
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Figure 3. In order to conduct a Y2H screen, NLRP12 had to be cloned into the PGBKT7 vector.
Only the front section of NLRP12 was successfully cloned.

Figure 4. PCR gel electrophoresis for NLRP12 using human NLRP12 forward and reverse
primers indicated about a 3300 bp NLRP12 insert.
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Figure 5. A gel electrophoresis image of a restriction enzyme digest showing the isolation of the
PGBKT7 plasmid and NLRP12 insert which were then cut out from the gel and purified for
ligation.

Figure 6. A gel electrophoresis image of picked colonies that were thought to contain the
successful NLRP12 insert within the PGBKT7 plasmid. The image reveals successful
NLRP12/PGBKT7 clones.
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Figure 7. A gel electrophoresis image of a restriction enzyme digest. A restriction enzyme digest
was completed a second time to ensure the NLRP12 insert was successfully cloned into the
PGBKT7 plasmid.

Figure 8. A colony PCR was conducted on 40 yeast colonies from the Y2H screen. These
samples were then sent for sequencing to obtain their identities.
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Figure 9. A diagram depicting an unknown protein interacting with NLRP12 via Y2H screen
promotes activation of reporter genes that encode the production of Tryptophan, Leucine,
Histidine, and Adenine allowing the yeast containing both plasmids to grow on media lacking all
four amino acids.

Figure 10. An image of Y2H plates against NLRP12 and other proteins (STIP1, SPATA22,
RNF2, CUL3, and COP9) that were shown to interact with NLRP12 in the first Y2H screen.
These plates confirmed a strong interaction between NLRP12 and COP9, RNF2, and CUL3.

43

Figure 11. A diagram depicting the specific mammalian expression vector that NLRP12 (fulllength) was cloned into.

Figure 12. A diagram depicting the specific mammalian expression vector containing the IFIT1
gene.
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Figure 13. A western blot using both anti-Flag (IFIT1, right half) and anti-Myc (NLRP12, left
half) antibodies revealed overexpression of both proteins was observed.

Figure 14. The CO-IP experiment revealed IFIT1 and NLRP12 do not interact via
overexpression of each protein within HEK 293 T Cells which was observed via Western Blot.
Lanes 2, 3 and 7 were immunoprecipitated with Myc antibody, lanes 4 and 9 were
immunoprecipitated with Flag antibody, and lane 5 was immunoprecipitated with Tubulin
(control) antibody.
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